Citius Pharmaceuticals, Inc

(NASDAQ:CTXR)

Latest On Citius Pharmaceuticals, Inc (CTXR):

Date/Time Type Description Signal Details
2023-05-12 22:21 ESTNewsCitius Pharmaceuticals GAAP EPS of -$0.07 misses by $0.02N/A
2023-05-04 10:53 ESTNewsCitius Pharmaceuticals slumps 16% on $15M offeringN/A
2023-04-24 17:08 ESTNewsCitius Pharma down 8% despite close to end of late-stage Mino-Lok trialN/A
2023-03-31 03:24 ESTNewsCitius extends gains on advancing efforts to spin off oncology assetN/A
2023-03-01 09:40 ESTNewsCitius Pharmaceuticals: Balanced Risk-Reward Bet, Near-Term CatalystsN/A
2023-02-26 09:00 ESTNewsCitius Pharmaceuticals: Diverse Development Portfolio Backs Up A Problematic Lead TherapyN/A
2023-02-11 14:43 ESTNewsCitius Pharmaceuticals GAAP EPS of -$0.02N/A
2022-12-23 06:31 ESTNewsCitius Pharmaceuticals GAAP EPS of -$0.23 beats by $0.01N/A
2022-12-02 03:43 ESTNewsCitius stock rises as I/ONTAK gets FDA review for rare blood cancerN/A
2022-11-22 00:39 ESTNewsCitius Pharmaceuticals secures $3.6M through NJEDAN/A
2022-11-08 10:30 ESTNewsCitius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 DaysN/A
2022-09-28 17:23 ESTNewsCitius Pharma submits biologics license application to FDA for immunotherapy I/ONTAKN/A
2022-09-24 00:46 ESTNewsCitius gains on clinical collaboration to study cancer candidateN/A
2022-08-12 01:01 ESTNewsCitius Pharmaceuticals GAAP EPS of -$0.06N/A
2022-07-13 00:39 ESTNewsCitius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAKN/A
2022-07-06 04:24 ESTNewsCitius Pharmaceuticals: Hoping For A Turnaround StrategyN/A
2022-05-25 15:29 ESTNewsCitius Pharma to spinoff its immunotherapy I/ONTAK into a new publicly-traded companyN/A
2022-05-13 09:56 ESTNewsCitius Pharmaceuticals GAAP EPS of -$0.05 beats by $0.02N/A
2022-05-06 23:53 ESTNewsCitius to add overseas sites to Phase 3 trial for antibiotic lock therapyN/A
2022-04-13 16:17 ESTNewsCritical Care Biopharma - Citius PharmaceuticalsN/A
2022-04-13 16:17 ESTNewsCitius Pharma realigns management to support commercialization of two late-stage productsN/A
2022-04-06 14:09 ESTNewsCitius stock soars 16% as I/ONTAK seen to equal discontinued cancer drug in phase 3 trialN/A
2022-03-28 19:19 ESTNewsCitius: 2022 Is A Year Of CatalystsN/A
2022-02-11 01:35 ESTNewsCitius Pharmaceuticals GAAP EPS of -$0.06 in-lineN/A
2021-12-16 05:04 ESTNewsCitius Pharmaceuticals reports FY resultsN/A
2021-09-26 17:36 ESTNewsCitius Pharmaceuticals, Inc.: Burning Cash Before CommercializationN/A
2021-09-07 11:31 ESTNewsCitius Pharmaceuticals acquires license for lymphoma treatment E7777 from Dr. Reddy'sN/A
2021-08-13 11:38 ESTNewsCitius Pharmaceuticals reports Q3 resultsN/A
2021-07-21 03:11 ESTNewsCitius Pharmaceuticals set to join Russell 2000 IndexN/A
2021-07-21 03:10 ESTNewsCitius Pharmaceuticals provides late-stage Mino-Lok trial timeline updateN/A
2021-07-21 03:03 ESTNewsCitius Pharmaceuticals adds John Laffey to scientific advisory boardN/A
2021-07-21 03:03 ESTNewsCitius: Halt For Superiority On The HorizonN/A
2021-07-21 02:45 ESTNewsCitius Pharma stock tanks 16% despite "positive" DMC recommendation to continue late-stage Mino-Lok trialN/A
2021-07-21 02:44 ESTNewsProvention Bio among healthcare gainers; Arrowhead Pharmaceuticals and Citius Pharma among losersN/A
2021-04-26 18:45 ESTNewsCitius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 resultsN/A
2021-04-17 21:55 ESTNewsChecking In On Citius PharmaceuticalsN/A
2021-02-21 23:25 ESTAnalyst RatingThe Analyst Target Price has increased from $5 to $6.Buy
2021-02-17 19:29 ESTNewsCitius Pharma slips 8% on capital raiseN/A
2021-02-12 11:25 ESTEarnings EstimateAn EPS average of $0.17 is estimated for the quarter ending on June 30, 2021.Buy
2021-02-12 07:29 ESTFinancialsCompany financials have been released.Neutral
2021-01-28 23:35 ESTAnalyst RatingThe Analyst Target Price has decreased from $5.5 to $5.Neutral
2021-01-25 15:21 ESTNewsCitius Pharma to raise $20M through share saleN/A
2020-12-18 11:32 ESTFinancialsCompany financials have been released.Neutral
2020-12-17 03:31 ESTEarnings EstimateAn EPS average of $2.22 is estimated for the 2022 year.Buy
2020-12-17 03:31 ESTEarnings EstimateAn EPS average of $0.24 is estimated for the quarter ending on March 31, 2021.Buy
2020-12-13 03:45 ESTFinancialsCompany financials have been released.Neutral
2020-12-06 23:29 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 07:38 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 15:32 ESTFinancialsCompany financials have been released.Neutral
2020-10-16 17:49 ESTNewsCitius Pharmaceuticals: Phase 3 Catalyst Countdown And Ready For Take OffN/A

About Citius Pharmaceuticals, Inc (CTXR):

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

CTXR Quotes by TradingView

See Advanced Chart

General

  • Name Citius Pharmaceuticals, Inc
  • Symbol CTXR
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 10
  • Last Split Factor1:15
  • Last Split Date2017-06-09
  • Fiscal Year EndSeptember
  • IPO Date2017-07-06
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.citiuspharma.com
View More

Valuation

  • Forward PE 1.29
  • Price/Book (Most Recent Quarter) 9.93
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.34
  • Next Year EPS Estimate $0.31
  • Next Quarter EPS Estimate $0.16
  • Return on Assets -44%
  • Return on Equity -93%
  • Earnings Per Share -$0.82
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 242.77 million
  • EBITDA -15601637
  • Analyst Target Price $6
  • Book Value Per Share $0.45
View More

Share Statistics

  • Shares Outstanding 125.79 million
  • Shares Float 67.62 million
  • % Held by Insiders 2215%
  • % Held by Institutions 13.89%
  • Shares Short 10.11 million
  • Shares Short Prior Month 2.8 million
  • Short Ratio 0.37
  • Short % of Float 9%
  • Short % of Shares Outstanding 8%
View More

Technicals

  • Beta 1.55
  • 52 Week High $2.5
  • 52 Week Low $0.44
  • 50 Day Moving Average 1.72
  • 200 Day Moving Average 1.21
View More

Dividends

  • Dividend Date 2017-06-09
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Citius Pharmaceuticals, Inc (CTXR) Dividend Calendar:

CTXR's last dividend payment was made to shareholders on June 9, 2017.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Citius Pharmaceuticals, Inc (CTXR) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-03$N/A-$0.15$0.16-193.75%
2020-09-302020-12-16$N/A-$0.07-$0.1030%
2020-06-302020-08-14$N/A-$0.11-$0.110%
2020-03-312020-05-14$N/A-$0.13-$0.11-18.18%
2019-12-312020-02-13$N/A-$0.15-$0.14-7.14%
2019-09-302019-12-16$N/A-$0.16-$0.14-14.29%
2019-06-302019-08-14$N/A-$0.20
2019-03-312019-05-15$N/A-$0.20-$0.200%
2018-12-312019-02-14$N/A-$0.22-$0.21-4.76%
2018-09-302018-12-11$N/A-$0.15
2018-06-302018-08-14$N/A-$0.19-$0.3240.63%
2018-03-312018-05-11$N/A-$0.44
2017-12-312018-03-20$N/A-$0.38
2017-09-302017-12-13$N/A-$0.44
2017-06-302017-06-30$N/A-$0.49
2017-03-312017-03-31$N/A-$0.55
2016-12-312016-12-31$N/A-$0.44
2016-09-302016-09-30$N/A-$0.53
2016-06-302016-06-30$N/A-$0.75
2016-03-312016-03-31$N/A-$0.35
2015-12-312015-12-31$N/A-$0.53
2015-09-302015-09-30$N/A-$0.40
2015-06-302015-06-30$N/A-$0.38
2015-03-312015-03-31$N/A-$0.17
2014-12-312014-12-31$N/A-$0.41

Citius Pharmaceuticals, Inc (CTXR) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Citius Pharmaceuticals, Inc (CTXR) Chart:

Citius Pharmaceuticals, Inc (CTXR) News:

Below you will find a list of latest news for Citius Pharmaceuticals, Inc (CTXR) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Citius Pharmaceuticals, Inc (CTXR) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-09-190.50CALL0 0529.1TRUE00
2025-09-1910.32CALL0 25262.27TRUE00
2025-09-191.50.1CALL1 3135.64FALSE0.10
2025-09-1920.1CALL0 1454337.53FALSE00
2025-09-192.50.18CALL0 235405.23FALSE00
2025-09-1950.03CALL0 3589.92FALSE00
2025-09-197.50CALL0 0655.7FALSE00
2025-09-190.50PUT0 0249.95FALSE00
2025-09-1910PUT0 0224.96FALSE00
2025-09-191.50PUT0 0197.96TRUE00
2025-09-1920PUT0 0142.81TRUE00
2025-09-192.51.36PUT1 1248.2TRUE1.360
2025-09-1950PUT0 0299.45TRUE00
2025-09-197.50PUT0 0477.95TRUE00
2025-10-170.50CALL0 0160.77TRUE00
2025-10-1710CALL0 0105.35TRUE00
2025-10-171.50.25CALL0 3196.06FALSE00
2025-10-1720CALL0 0201.18FALSE00
2025-10-172.50.08CALL0 79275.58FALSE00
2025-10-1750CALL0 0420.35FALSE00
2025-10-177.50CALL0 0467.31FALSE00
2025-10-170.50PUT0 0708.51FALSE00
2025-10-1710PUT0 0129.39FALSE00
2025-10-171.50PUT0 0142.82TRUE00
2025-10-1720PUT0 0155.25TRUE00
2025-10-172.51.35PUT1 0174.03TRUE1.350
2025-10-1750PUT0 0299.57TRUE00
2025-10-177.50PUT0 0269.69TRUE00
2025-11-210.50.8CALL0 3347.44TRUE00
2025-11-2110.81CALL0 894.73TRUE00
2025-11-211.50.25CALL0 120116.22FALSE00
2025-11-2120.1CALL0 729136.75FALSE00
2025-11-212.50.06CALL0 1881140.28FALSE00
2025-11-2150.08CALL0 1026208.26FALSE00
2025-11-217.50.05CALL0 1049367.49FALSE00
2025-11-210.50PUT0 0560.06FALSE00
2025-11-2110.4PUT0 1165.84FALSE00
2025-11-211.50PUT0 093.32TRUE00
2025-11-2120PUT0 0146.23TRUE00
2025-11-212.51.2PUT0 42163.77TRUE00
2025-11-2153.8PUT50 53181.26TRUE3.80
2025-11-217.56.1PUT0 0220.82TRUE00
2026-02-200.50.8CALL0 6171.6TRUE00
2026-02-2010.6CALL1 41157.07TRUE0.60
2026-02-201.50.4CALL0 21147.44FALSE00
2026-02-2020.17CALL8 189102.11FALSE0.170
2026-02-202.50.1CALL250 39398.7FALSE-0.05-0.33
2026-02-2050.1CALL0 204136.49FALSE00
2026-02-207.50.05CALL0 360223.19FALSE00
2026-02-200.50.11PUT0 4297FALSE00
2026-02-2010PUT0 0137.65FALSE00
2026-02-201.50.43PUT0 4119.33TRUE00
2026-02-2020PUT0 0121.83TRUE00
2026-02-202.50PUT0 0143.34TRUE00
2026-02-2053.7PUT0 1137.78TRUE00
2026-02-207.50PUT0 0227.4TRUE00

Latest CTXR Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST110$0.9501
Jun 13, 2022 7:59 PM EST1000$0.9501
Jun 13, 2022 7:59 PM EST200$0.95
Jun 13, 2022 7:59 PM EST100$0.9501
Jun 13, 2022 7:59 PM EST73$0.9501

Citius Pharmaceuticals, Inc (CTXR) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020015902/0001213900-20-015902-index.htm
2020-04-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1506251/000000000020003314/0000000000-20-003314-index.htm
2020-06-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1506251/000000000020005207/0000000000-20-005207-index.htm
2020-09-18UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1506251/000000000020008820/0000000000-20-008820-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1506251/000091957420000776/0000919574-20-000776-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1506251/000091957420001645/0000919574-20-001645-index.htm
2019-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390019020117/0001213900-19-020117-index.htm
2019-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390019020119/0001213900-19-020119-index.htm
2019-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390019020122/0001213900-19-020122-index.htm
2019-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390019020124/0001213900-19-020124-index.htm
2019-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390019020126/0001213900-19-020126-index.htm
2019-11-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390019021804/0001213900-19-021804-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390019022028/0001213900-19-022028-index.htm
2019-12-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1506251/000121390019026259/0001213900-19-026259-index.htm
2019-12-16S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1506251/000121390019026269/0001213900-19-026269-index.htm
2019-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390019026521/0001213900-19-026521-index.htm
2019-12-20DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1506251/000121390019026699/0001213900-19-026699-index.htm
2019-12-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1506251/000121390019026703/0001213900-19-026703-index.htm
2020-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020001566/0001213900-20-001566-index.htm
2020-02-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020002349/0001213900-20-002349-index.htm
2020-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020002480/0001213900-20-002480-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020003094/0001213900-20-003094-index.htm
2020-02-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1506251/000121390020003577/0001213900-20-003577-index.htm
2020-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020003992/0001213900-20-003992-index.htm
2020-02-18424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1506251/000121390020004157/0001213900-20-004157-index.htm
2020-02-18424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1506251/000121390020004160/0001213900-20-004160-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020004257/0001213900-20-004257-index.htm
2020-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020004698/0001213900-20-004698-index.htm
2020-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020008291/0001213900-20-008291-index.htm
2020-04-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020008765/0001213900-20-008765-index.htm
2020-04-10S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1506251/000121390020008985/0001213900-20-008985-index.htm
2020-04-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1506251/000121390020009473/0001213900-20-009473-index.htm
2020-04-24424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1506251/000121390020010056/0001213900-20-010056-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020010246/0001213900-20-010246-index.htm
2020-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020010431/0001213900-20-010431-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020011769/0001213900-20-011769-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1506251/000121390020012286/0001213900-20-012286-index.htm
2020-05-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1506251/000121390020012584/0001213900-20-012584-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020012809/0001213900-20-012809-index.htm
2020-05-19DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020012897/0001213900-20-012897-index.htm
2020-05-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020013443/0001213900-20-013443-index.htm
2020-06-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020013937/0001213900-20-013937-index.htm
2020-06-05S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1506251/000121390020014231/0001213900-20-014231-index.htm
2020-06-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1506251/000121390020014691/0001213900-20-014691-index.htm
2020-06-12424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1506251/000121390020014875/0001213900-20-014875-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020015902/0001213900-20-015902-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020017075/0001213900-20-017075-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020017080/0001213900-20-017080-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020017083/0001213900-20-017083-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020017086/0001213900-20-017086-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020017089/0001213900-20-017089-index.htm
2020-07-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020017179/0001213900-20-017179-index.htm
2020-07-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020017402/0001213900-20-017402-index.htm
2020-07-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020017556/0001213900-20-017556-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020017558/0001213900-20-017558-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020020036/0001213900-20-020036-index.htm
2020-08-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1506251/000121390020020405/0001213900-20-020405-index.htm
2020-08-05FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020020409/0001213900-20-020409-index.htm
2020-08-06FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020020467/0001213900-20-020467-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1506251/000121390020020900/0001213900-20-020900-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020021164/0001213900-20-021164-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1506251/000121390020022331/0001213900-20-022331-index.htm
2020-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020023749/0001213900-20-023749-index.htm
2020-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020023818/0001213900-20-023818-index.htm
2020-09-11S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1506251/000121390020026248/0001213900-20-026248-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020026724/0001213900-20-026724-index.htm
2020-09-18CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1506251/000121390020027371/0001213900-20-027371-index.htm
2020-09-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020027841/0001213900-20-027841-index.htm
2020-09-25424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1506251/000121390020028490/0001213900-20-028490-index.htm
2020-09-25POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1506251/000121390020028494/0001213900-20-028494-index.htm
2020-09-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020028857/0001213900-20-028857-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020030788/0001213900-20-030788-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020030790/0001213900-20-030790-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020030791/0001213900-20-030791-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020030792/0001213900-20-030792-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020030793/0001213900-20-030793-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020030794/0001213900-20-030794-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020030795/0001213900-20-030795-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1506251/000121390020030797/0001213900-20-030797-index.htm
2020-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020030802/0001213900-20-030802-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1506251/000121390020033152/0001213900-20-033152-index.htm
2020-04-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1506251/999999999520000856/9999999995-20-000856-index.htm
2020-06-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1506251/999999999520001419/9999999995-20-001419-index.htm
2020-09-25EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1506251/999999999520002581/9999999995-20-002581-index.htm
2020-09-30EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1506251/999999999520002620/9999999995-20-002620-index.htm